Plum SEC
Menu
Korean Market
Privacy Policy
Korean Market
Star Rating
Reset (View All)
★★★★★
★★★★
★★★
★★
★
★
★
★★
★★★
★★★★
★★★★★
All Disclosures
Search
OWNR
Chong Kun Dang Pharmaceutical
★
Kopernik Global Investors Increases Stake in Chong Kun Dang to 7.21% via Open Market Purchases, Signaling Institutional Confidence Without Management Influence
06/01/2026, 05:14 PM
EXCH
Chong Kun Dang Pharmaceutical
★
Chong Kun Dang's 2025 Earnings Decline and 54% Dividend Cut Amid Governance Improvements: Shareholder Value Recovery Key
06/01/2026, 03:31 PM
EXCH
Chong Kun Dang Pharmaceutical
★★★
Preliminary Q1 2026: Sales +12%, Operating Profit +37% YoY
05/16/2026, 07:51 PM
PERI
Chong Kun Dang Pharmaceutical
★★
Chong Kun Dang Q1 2026: Wegovy Sales Surge & R&D Investment Growth
05/15/2026, 04:50 PM
EXCH
Chong Kun Dang Pharmaceutical
★
CKD-339 Hypertension Drug: MFDS Phase 3 Clinical Trial Application Submitted
05/14/2026, 03:44 PM
EXCH
Chong Kun Dang Pharmaceutical
★
Sales Up 6.7% but Operating Profit Down 19%, Net Profit Plunges 30% (Preliminary)
05/10/2026, 07:00 PM
OWNR
Chong Kun Dang Pharmaceutical
★
Chong Kun Dang Holdings Files Large Shareholding Report (No Specific Details)
05/10/2026, 07:00 PM
OWNR
Chong Kun Dang Pharmaceutical
★
Chong Kun Dang Holdings Files Large Shareholding Report (No Changes)
05/03/2026, 07:00 AM